Emergent BioSolutions Inc. has announced a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services. This contract is for the supply of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a two-dose anthrax vaccine intended for post-exposure prophylaxis. Deliveries are set to commence within this calendar year and are expected to be completed by March 2026. This follows a previous $50 million contract modification announced in December 2024. The initiative is part of an ongoing collaboration with the U.S. government to ensure the availability of medical countermeasures against anthrax, a Tier 1 biological threat.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521614-en) on September 02, 2025, and is solely responsible for the information contained therein.